Karyopharm Therapeutics Inc. 即将与美国食品药品监督管理局（FDA）举行会议，重点讨论其Sentry临床试验所获得的数据结果，以及后续提交补充新药申请（sNDA）的潜在可能性。
Karyopharm Therapeutics Inc. 即将与美国食品药品监督管理局（FDA）举行会议，重点讨论其Sentry临床试验所获得的数据结果，以及后续提交补充新药申请（sNDA）的潜在可能性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.